<DOC>
	<DOCNO>NCT02395744</DOCNO>
	<brief_summary>The purpose COPPER - B study ass feasibility , safety , initial efficacy paclitaxel administration use OPC prevention restenosis infrapopliteal de novo restenotic lesion occlusion use novel catheter , OPC .</brief_summary>
	<brief_title>The COPPER-B Trial</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>General Willing able provide inform consent comply study requirement ; Candidate infrapopliteal percutaneous intervention ; Must ≥ 18 year age ; Rutherford category 36 ; Willing able tolerate dual antiplatelet therapy ( DAPT ) minimum one ( 1 ) month ; Labwork within acceptable limit accord standard care ; INR &lt; 2.0 warfarin warfarin ; Sheath size use interventional procedure 6F , 7F , 8F . General Life expectancy &lt; one ( 1 ) year ; Planned amputation prior procedure ; Pregnancy nursing ( pregnancy test require woman childbearing capability ≤ 7 day prior index procedure ) ; Previous intervention target vessel drug elute balloon , drug delivery catheter ; Acute limb ischemia ; Known allergy paclitaxel ; Known hypersensitivity drug manufacture Cremophor® EL ( polyoxyethylated castor oil ; e.g . Drugs contain polyoxyethylated castor oil drug miconazole , cyclosporine injection , nelfinavir mesylate , saperconazole , tacrolimus , xenaderm ointment ) ; Known allergy anticoagulant ; Known TRUE acetylsalicylic acid ( ASA ) allergy ; Use glycoprotein ( GP ) IIb/IIIa inhibitor procedure visit within 30 day prior index procedure ; Target lesion treat cryoplasty balloon time index procedure ; Current enrollment another investigational device drug study ; After obtain informed consent , point introduction OPC , investigator determines study subject appropriate study ; Hemorrhagic stroke within three ( 3 ) month ; Renal failure chronic kidney disease GFR ≤30 ml/min MDRD GFR ≤30 ml/min per 1.73 m2 ( serum creatinine ≥2.5 mg/L within 30 day index procedure patient dialysis ) ; Prior vascular surgery index limb . Angiographic Inclusion Criteria Reference vessel diameter ( RVD ) ≥ 2mm ≤ 4mm ; Single multiple lesion infrapopliteal artery ( AT , PT , peroneal ) ; If single lesion treatment , minimum lesion length require 2cm ; Lesion location must area origin trifurcation vessel ankle ( top talus bone ) ; Minimum one vessel runoff ; Preintervention percent DS ≥ 70 % ; Target vessel reconstitute at/above ankle ; Infrapopliteal treatment prior infrapopliteal OPC treatment result ≤ 30 % residual stenosis ; Infrapopliteal interventional treatment length within area 1cm level knee joint malleolus , except case anomalous takeoff infrapopliteal artery come midknee joint . Angiographic Exclusion Criteria Flow limit dissection require stent placement ; Post PTA residual stenosis &gt; 30 % visualized treating physician ; Perforation require covered stent ; Lesion trifurcation ; Instent restenosis target vessel ; Significant ( ≥ 50 % DS ) inflow lesion occlusion leave untreated ipsilateral Iliac , SFA , popliteal artery proximal target lesion ; Lesions target vessel treated OPC ; Visible thrombus target artery proximal target artery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>